New Development in Rare Pediatric Epilepsy: Biocodex Announces the Development of DIACOMIT® (stiripentol) Oral Suspension, a New Formulation to Aid in the Treatment of Dravet Syndrome in Young Children
Hand-out
Press Releases
Biocodex, Inc.  
November 14, 2024

New Development in Rare Pediatric Epilepsy: Biocodex Announces the Development of DIACOMIT® (stiripentol) Oral Suspension, a New Formulation to Aid in the Treatment of Dravet Syndrome in Young Children

BEDMINSTER, N.J., Nov. 14, 2024 /PRNewswire/ -- The global pharmaceutical company, Biocodex, a long-time pioneer in the treatment of rare pediatric diseases, is proud to announce they are developing a

avatar profile Olean Times Herald

Olean Times Herald


Local & Social